Jasper Therapeutics Inc
JSPR
NASDAQ
Biotechnology
$0.79
USD
-0.07 (-8.46%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $24.49M
Volume 552.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-55.73M
TTM
+29.3%
YoY
Operating Cash Flow
$-68.87M
TTM
+1.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.6 | 5.9 | 4.8 | 4.5 | 5.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 21.8 | 27.1 | 19.2 | 15.8 | 11.0 |
Operating Income | -21.8 | -27.1 | -19.2 | -15.8 | -11.0 |
EBITDA | -21.5 | -26.8 | -18.9 | -15.5 | -10.9 |
Other Income / Expense | -0.1 | -0.1 | 0.1 | 6.4 | 9.6 |
Total Other Income / Expense | 0.6 | 0.4 | 0.4 | 6.7 | 9.8 |
Income Before Income Taxes | -21.2 | -26.7 | -18.7 | -9.1 | -1.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -21.2 | -26.7 | -18.7 | -9.1 | -1.2 |
Consolidated Net Income / Loss | -21.2 | -26.7 | -18.7 | -9.1 | -1.2 |
Net Income Attributable to Common Shareholders | -21.2 | -26.7 | -18.7 | -9.1 | -1.2 |
Basic EPS | -$1.41 | -$1.74 | -$1.13 | -$0.31 | -$0.04 |
Diluted EPS | -$1.41 | -$1.74 | -$1.13 | -$0.31 | -$0.04 |
Basic Shares Outstanding | 15.0M | 15.3M | 16.6M | 29.7M | 28.7M |
Diluted Shares Outstanding | 15.0M | 15.3M | 16.6M | 29.7M | 28.7M |